LAA-Okkluder und PFO-Verschluss

ZUSAMMENFASSUNG

Der interventionelle perkutane Vorhofohrverschluss (LAAC) bietet eine Alternative für Ärzte, die einer komplizierten Nutzen-Risiko-Analyse bei Patienten mit Vorhofflimmern (VHF) gegenüberstehen, die aufgrund ihres Schlaganfallrisikos eine orale Antikoagulation (OAK) erhalten sollten, aber auch ein hohes Blutungsrisiko haben. Eine Steigerung dieses Bewusstseins in verschiedenen medizinischen Disziplinen hinweg könnte eine alternative Strategie zur Schlaganfallprävention für Patienten darstellen, die derzeit nicht ausreichend geschützt sind.

• Literatur

• 1 Connolly S, Ezekowitz M, Yusuf S. et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
• 2 Patel M, Mahaffey K, Garg J. et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
• 3 Saperas E, Videla S, Dot J. et al Risk factors for recurrence of acute gastrointestinal bleeding from angiodysplasia. Eur J Gastroenterol Hepat 2009; 21: 1333-1339
• 4 Gladstone D, Bui E, Fang J. et al Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240
• 5 Flaherty M, Kissela B, Woo D. et al The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68: 116-121
• 6 Robert-Ebadi H, Righini M. Anticoagulation in the elderly. Pharmaceuticals 2010; 3: 3543-3569
• 7 Goldstein J, Greenberg S. Should anticoagulation be resumed after intracerebral hemorrhage?. Cleveland Clin J 2010; 77: 791-799
• 8 Aonuma K, Yamasaki H, Nakamura M. et al Percutaneous Watchman left atrial appendage closure for Japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism – first results from the SALUTEtrial. Circ J 2018; 82: 2946-2953
• 9 Holmes Jr DR, Kar S, Price MJ. et al Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 64: 1-12
• 10 Reddy VY, Holmes D, Doshi SK. et al Safety of percutaneous left atrial appendage closure: results from the Watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access registry. Circulation 2011; 123: 417-424
• 11 Reddy VY, Doshi SK, Kar S. et al 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70: 2964-2975
• 12 Boersma LV, Ince H, Kische S. et al Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology. Circ Arrhythm Electrophysiol 2019; 12: e006841
• 13 Holmes DR, Reddy VY, Buchbinder M. et al The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J 2017; 189: 68-74
• 14 Lakkireddy D, Windecker S, Thaler D. et al Rationale and design for Amplatzer Amulet left atrial appendage occluder IDE randomized controlled trial (Amulet IDE trial). Am Heart J 2019; 211: 45-53
• 15 Schnupp S, Ajmi I, Brachmann J, Mahnkopf C. Lifetech LAmbre: a new promising and novel device in the interventional stroke prevention. Future Cardiol 2019; 15: 405-410
• 16 January CT, Wann LS, Calkins H. et al 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74: 104-132
• 17 Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59: 17-20
• 18 Lechat P, Mas JL, Lascault G. et al Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148-1152
• 19 Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?. Stroke 2009; 40: 2349-2355
• 20 Mojadidi MK, Elgendy AY, Elgendy IY. et al Transcatheter patent foramen ovale closure after cryptogenic stroke: an updated meta-analysis of randomized trials. JACC Cardiovasc Interv 2017; 10: 2228-2230
• 21 Vaduganathan M, Qamar A, Gupta A. et al Patent foramen ovale closure for secondary prevention of cryptogenic stroke: updated meta-analysis of randomized clinical trials. Am J Med 2018; 131: 575-577
• 22 Kent DM, Ruthazer R, Weimar C. et al An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81: 619-625
• 23 Singh HS, Katchi F, Naidu SS. PFO closure for cryptogenic stroke: a review and clinical treatment algorithm. Cardiol Rev 2017; 25: 147-157
• 24 Vaduganathan M, Qamar A, Gupta A. et al Patent foramen ovaleclosure for secondary prevention of cryptogenic stroke: updatedmeta-analysis of randomized clinical trials. Am J Med 2018; 131: 575-577
• 25 Furlan AJ, Reisman M, Massaro J. et al Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991-999
• 26 Meier B, Kalesan B, Mattle HP. et al Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083-1091
• 27 Diener HC, Grau A, Baldus S. et al Kryptogener Schlaganfall und offenes Foramen ovale, S2e-Leitlinie. 2018 in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien abgerufen am 17. Januar 2020